Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Investors continue to prefer the stability of the U.S. relative to emerging markets. The recent declines recorded in emerging markets and their currencies suggest global risk aversion. U.S. equity markets are, by contrast, not showing any significant signs of coming unhinged as a result of this rout in emerging markets.  In this report we examine the factors likely to impact the U.S. equity markets, and explore actionable opportunities within the Technology, Consumer Discretionary, and Health Care Sectors.

Investors continue to prefer the stability of the U.S. relative to emerging markets. The recent declines recorded in emerging markets and their currencies suggest global risk aversion. U.S. equity markets are, by contrast, not showing any significant signs of coming unhinged as a result of this rout in emerging markets.  In this report we examine the factors likely to impact the U.S. equity markets, and explore actionable opportunities within the Technology, Consumer Discretionary, and Health Care Sectors.

U.S. Equity Strategy: Cyclicals Remain Leadership - Staples & Utilities Are Strengthening

On cue, outperformance last week and yesterday from cyclicals led the S&amp;P 500 to new all-time highs while defensive Sectors lagged. Additionally, weakness in the US dollar has allowed foreign equities to recover substantially, to the point where the major int’l ETFs (ACWX, EFA, and EEM) are on the cusp of bullish inflections topside downtrends. In today’s report outline our view of the U.S. equity market ad highlight attractive Groups and stocks within Health Care and Technology.

On cue, outperformance last week and yesterday from cyclicals led the S&amp;P 500 to new all-time highs while defensive Sectors lagged. Additionally, weakness in the US dollar has allowed foreign equities to recover substantially, to the point where the major int’l ETFs (ACWX, EFA, and EEM) are on the cusp of bullish inflections topside downtrends. In today’s report outline our view of the U.S. equity market ad highlight attractive Groups and stocks within Health Care and Technology.

U.S. Strategy: Sentiment Improving, Upgrading Manufacturing

As the S&amp;P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we remain constructive overall, our expectations are tempered as the market finds itself a crossroad.  In today’s report we provide our U.S. equity strategy synopsis, and also highlight attractive stocks within the Health Care Sector.

As the S&amp;P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we remain constructive overall, our expectations are tempered as the market finds itself a crossroad.  In today’s report we provide our U.S. equity strategy synopsis, and also highlight attractive stocks within the Health Care Sector.

S&P 500: Outlook Constructive but Concerns Remain

United States

QuidelOrtho Corporation provides health care services. The Company offers technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

QuidelOrtho (QDEL US)

U.S. Equity Strategy: Cyclicals Remain Leadership - Staples & Utilities Are Strengthening

Investors continue to prefer the stability of the U.S. relative to emerging markets. The recent declines recorded in emerging markets and their...

Vermilion Research

U.S. Strategy: Sentiment Improving, Upgrading Manufacturing

On cue, outperformance last week and yesterday from cyclicals led the S&P 500 to new all-time highs while defensive Sectors lagged....

Vermilion Research

S&P 500: Outlook Constructive but Concerns Remain

As the S&P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)